Literature DB >> 21919238

[Analysis of total cost of treatment of patients with inflammatory bowel diseases].

L B Lazebnik, A I Parfenov, M G Guseĭnzade, O V Kniazev, L I Efremov.   

Abstract

The article stresses that among the chronic diseases of the digestive tract occupy a special place inflammatory bowel disease (IBD)--UC and BC with multiple complications and the onset of early disability of patients. IBD is a serious issue of gastroenterology, since their etiology remains unknown, and specific treatment hasn't yet been developed. Finally, the prevalence and social significance of IBD also occupy a leading place among the diseases of the digestive organs, since they are characterized by recurrent course and have adverse medical and social prognosis. According to sources in various countries annually spend huge money for treatment of IBD. The costs of IBD depends on the severity and nature of complications, duration of illness, the choice of treatment, frequency of hospitalization and the patient's country of residence. Various studies demonstrate the feasibility of using more modern efficient methods of treatment (MSSC + therapy) to reduce the incidence of complications associated with IBD, resulting in huge costs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21919238

Source DB:  PubMed          Journal:  Eksp Klin Gastroenterol        ISSN: 1682-8658


  1 in total

1.  The role of CXCR3 in DSS-induced colitis.

Authors:  Belal Chami; Amanda W S Yeung; Caryn van Vreden; Nicholas J C King; Shisan Bao
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.